the aid library

LIST OPTIONS

Filter

2705

The reality of managing asthma in sub-Saharan Africa – Priorities and strategies for improving care

Mortimer, K.; Masekela, R.; Ozoh, O.; et al. (2022) CC2

Asthma is the most common non-communicable disease in children and remains one of the most common throughout the life course. The great majority of the burden of this disease is seen in low-income and middle-income countries (LMICs), which have disproportionately high asthma-related mortality relati... more

Download (477)

View PDF (664)

Trends in Child Health in Nigeria, 2003– 2013

Winter, Rebecca, Akinlo, Ambrose, and Lia Florey ICF International (2016) C2

DHS Further Analysis Reports No. 103

Download (784)

View PDF (1412)

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti... more

Download (611)

View PDF (1187)

The Wise List 2015

Stockholm Drug and Therapeutics Committee (2015) C_WHO

with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden

Download (1495)

View PDF (1787)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (294)

View PDF (309)

TB Advocacy Guide - For People who use Drugs

hit.org.uk; INPUD (2019) C2

Accessed: 19.10.2019

Download (473)

View PDF (675)

Community Ear & Hearing Health - Volume 9 • Issue 12 (2012)

Community Ear & Hearing Health (2012) C2

This journal is funded by CBM

Download (469)

View PDF (696)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (1073)

View PDF (2874)

Training Course on the Management of Severe Malnutrition Course Director Guide

WHO WHO (2002)

Download (1699)

View PDF (1941)

A Framework for Integrating Childhood Tuberculosis into Community-based Child Health Care

Detjen A, Gnanashanmugam D, Talens A International Union Against Tuberculosis and Lung Disease (The Union), CORE Group (2013) C_WHO

Download (338)

View PDF (489)

Improving Prison Conditions by Strengthening the Monitoring of HIV, HCV, TB and Harm Reduction (Portugal)

N. H. Ponters, A. P. Dores CIES IUL; ISCTE IUL; European Union (2015) C2

Mapping Report - Portugal

Download (5786)

View PDF (1796)

Pharmaceutical management and prescribing pattern of antimalarial drugs in the public health facilities in Dar-es-Salaam, Tanzania

Richard Sebastian Silumbe (2011) C1

Master of Science in Pharmaceutical Management Dissertation

Download (602)

View PDF (775)

Epidemic meningitis surveillance in the African meningitis belt

World Health Organization WHO (2014) C_WHO

Download (2245)

View PDF (2133)

WHO Safe Childbirth Checklist Implementation Guide
recommended

World Health Organization WHO (2015) C_WHO

This implementation guide has been developed to help birth attendants and health-care leaders successfully launch and sustain use of the WHO Safe Childbirth Checklist. Development, use and implementation of the Checklist are described in this guide. It covers how to introduce and ensure continuous ... more

Download (1069)

View PDF (1337)

WHO recommendations for prevention and treatment of maternal peripartum infections

World Health Organization WHO (2015) C_WHO

Download (632)

View PDF (882)

Tanzania Service Provision Assessement Survey (TSPA) 2014-2015 Key Findings

Ministry of Health and Social Welfare, Dar es Salaam, Ministry of Health, Zanzibar, National Bureau of Statistics, Zanzibar, Tanzania, and ICF International (2016) C1

Download (732)

View PDF (902)

Communicable disease threats report, 11 November 2017

European Centre for Disease Prevention and Control (2017) C1

The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 5-11 November 2017 and includes updates on measles, rubella, chikungunya, West Nile virus, Plague, monkeypox, legionnair... more